PS
ALLO icon

Pinney & Scofield’s Allogene Therapeutics ALLO Stock Holding History

Pinney & Scofield’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$399 Hold
192
– – ﹤0.01% 229
2026
Q1 		$468 Hold
192
– – ﹤0.01% 239
2025
Q4 		$263 Hold
192
– – ﹤0.01% 210
2025
Q3 		$238 Hold
192
– – ﹤0.01% 216
2025
Q2 		$217 Hold
192
– – ﹤0.01% 219
2025
Q1 		$280 Hold
192
– – ﹤0.01% 216
2024
Q4 		$409 Buy
+192
New +$474 ﹤0.01% 223

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pinney & Scofield's ALLO Position: Q2 2026 in Review

Pinney & Scofield held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 192 shares worth $399. The position accounts for ﹤0.01% of the portfolio, ranked #229.

Pinney & Scofield first reported a position in ALLO in Q4 2024 and has held it in 7 quarters since. The position peaked at $468 in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Pinney & Scofield held 192 shares of Allogene Therapeutics worth $399 as of Q2 2026.
  • Pinney & Scofield left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Pinney & Scofield's portfolio in Q2 2026, its #229 holding.
  • Pinney & Scofield first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Pinney & Scofield's Allogene Therapeutics position peaked at $468 in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Pinney & Scofield's 13F filing for Q2 2026, filed 7 Aug 2026.